All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [
Internalization
Neovasculature
Non-prostate cancer
Tumor retention
[177Lu]-PSMA-RL
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
21
08
2024
accepted:
29
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
epublish
Résumé
The main objective is to discuss why treatment of non-prostate cancers with [ [ Rapid tumor washout of [
Sections du résumé
BACKGROUND
BACKGROUND
The main objective is to discuss why treatment of non-prostate cancers with [
CASE PRESENTATION
METHODS
[
CONCLUSION
CONCLUSIONS
Rapid tumor washout of [
Identifiants
pubmed: 39404984
doi: 10.1186/s13550-024-01156-9
pii: 10.1186/s13550-024-01156-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95Subventions
Organisme : Ostfold Hospital, Kalnes
ID : Ostfold Hospital, Kalnes
Informations de copyright
© 2024. The Author(s).
Références
Wang JH, Kiess AP. PSMA-targeted therapy for non-prostate cancers. Front Oncol. 2023;13:1220586.
doi: 10.3389/fonc.2023.1220586
pubmed: 37645427
pmcid: 10461313
Van de Wiele C, Sathekge M, de Spiegeleer B, et al. PSMA expression on neovasculature of solid tumors. Histol Histopathol. 2020;35:919–27.
pubmed: 32282924
Pozzessere C, Bassanelli M, Ceribelli A, Rasul S, Li S, Prior JO, Cicone F. Renal cell carcinoma: the oncologist asks, can PSMA PET/CT answer? Curr Urol Rep. 2019;20:68.
doi: 10.1007/s11934-019-0938-9
pubmed: 31605269
Sjögreen Gleisner K, Chouin N, Gabina PM, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49:1778–809.
doi: 10.1007/s00259-022-05727-7
pubmed: 35284969
pmcid: 9015994
Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of
doi: 10.2967/jnumed.118.219352
pubmed: 30291192
Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, Wester HJ. Radiohybrid ligands: a Novel Tracer Concept Exemplified by
doi: 10.2967/jnumed.119.234922
pubmed: 31862804
pmcid: 7198388
Zhang J, Schuchardt C, Chen X, Baum RP. Rapid Tumor Washout of 177Lu-PSMA Radioligand in Renal Cell Carcinoma. Clin Nucl Med. 2023;48:732–4.
doi: 10.1097/RLU.0000000000004725
pubmed: 37276536
Hirmas N, Leyh C, Sraieb M, et al.
doi: 10.2967/jnumed.120.257915
pubmed: 33509970
pmcid: 8882890
Graef J, Bluemel S, Brenner W, et al. [
doi: 10.2967/jnumed.122.264850
pubmed: 37116918
Kunikowska J, Charzyńska I, Kuliński R, Pawlak D, Maurin M, Królicki L. Tumor uptake in glioblastoma multiforme after IV injection of [
doi: 10.1007/s00259-020-04715-z
pubmed: 32040612
pmcid: 7188710
Rupp NJ, Umbricht CA, Pizzuto DA, et al. First clinicopathologic evidence of a Non-PSMA-Related uptake mechanism for
doi: 10.2967/jnumed.118.222307
pubmed: 30737300
Nguyen DP, Xiong PL, Liu H, et al. Induction of PSMA and internalization of an Anti-PSMA mAb in the vascular compartment. Mol Cancer Res. 2016;14:1045–53.
doi: 10.1158/1541-7786.MCR-16-0193
pubmed: 27458033
Lau J, et al. Insight into the development of PET radiopharmaceuticals for Oncology. Cancers. 2020;12:1312.
doi: 10.3390/cancers12051312
pubmed: 32455729
pmcid: 7281377
El Fakiri M, Ayada N, Müller M, et al. Development and preclinical evaluation of [
doi: 10.2967/jnumed.123.267043
pubmed: 38423784
Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted alpha-particle therapy: a review of current trials. Int J Mol Sci. 2023;24:11626.
doi: 10.3390/ijms241411626
pubmed: 37511386
pmcid: 10380274
Kelch ID, Bogle G, Sands GB, Phillips AR, LeGrice IJ, Dunbar PR. Organ-wide 3D-imaging and topological analysis of the continuous microvascular network in a murine lymph node. Sci Rep. 2015;5:16534.
doi: 10.1038/srep16534
pubmed: 26567707
pmcid: 4645097
Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate Cancer by PET/CT: Biodistribution in humans, Radiation Dosimetry, and first evaluation of Tumor lesions. J Nucl Med. 2015;56:1697–705.
doi: 10.2967/jnumed.115.161299
pubmed: 26294298
Delbart W, Karabet J, Marin G, et al. Understanding the Radiobiological mechanisms Induced by
doi: 10.3390/ijms232012369
pubmed: 36293222
pmcid: 9604190
Loktev A, Lindner T, Mier W, et al. A tumor-imaging Method Targeting Cancer-Associated fibroblasts. J Nucl Med. 2018;59:1423–29.
doi: 10.2967/jnumed.118.210435
pubmed: 29626120
pmcid: 6126438
Lindner T, Loktev A, Giesel F, Kratochwil C, Altmann A, Haberkorn U. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem. 2019;4:16.
doi: 10.1186/s41181-019-0069-0
pubmed: 31659499
pmcid: 6658625